MICAFUNGIN Drug Patent Profile
✉ Email this page to a colleague
When do Micafungin patents expire, and what generic alternatives are available?
Micafungin is a drug marketed by Endo Operations, Teva Pharms Usa Inc, Baxter Hlthcare Corp, Apotex, Biocon Pharma, Fresenius Kabi Usa, Hikma, Jiangsu Hansoh Pharm, Meitheal, Xellia Pharms Aps, and Zydus Pharms. and is included in eleven NDAs.
The generic ingredient in MICAFUNGIN is micafungin sodium. There are eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the micafungin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Micafungin
A generic version of MICAFUNGIN was approved as micafungin sodium by FRESENIUS KABI USA on May 17th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MICAFUNGIN?
- What are the global sales for MICAFUNGIN?
- What is Average Wholesale Price for MICAFUNGIN?
Summary for MICAFUNGIN
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 35 |
| Clinical Trials: | 58 |
| Patent Applications: | 1,388 |
| Drug Prices: | Drug price information for MICAFUNGIN |
| What excipients (inactive ingredients) are in MICAFUNGIN? | MICAFUNGIN excipients list |
| DailyMed Link: | MICAFUNGIN at DailyMed |
Recent Clinical Trials for MICAFUNGIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wake Forest University Health Sciences | Phase 4 |
| Scynexis, Inc. | Phase 3 |
| Yung Shin Pharm. Ind. Co., Ltd. | Phase 4 |
Pharmacology for MICAFUNGIN
| Drug Class | Echinocandin Antifungal |
US Patents and Regulatory Information for MICAFUNGIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | MICAFUNGIN | micafungin sodium | POWDER;INTRAVENOUS | 212156-001 | Jun 16, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Meitheal | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 215381-001 | Sep 28, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Baxter Hlthcare Corp | MICAFUNGIN IN SODIUM CHLORIDE 0.9% | micafungin sodium | SOLUTION;INTRAVENOUS | 216142-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Usa Inc | MICAFUNGIN | micafungin sodium | POWDER;INTRAVENOUS | 212125-002 | Jul 30, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 207344-001 | May 17, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Xellia Pharms Aps | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 211713-001 | Jun 2, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Apotex | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 208366-001 | Nov 5, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
